GHRP-6
Aliases: Growth Hormone-Releasing Hexapeptide
Last verified: 2026-09-23
The short version
First-generation GHRP — reliable GH spike but pronounced ghrelin-like hunger, so it is used by those struggling to gain mass. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Clinically investigated in the 1990s; never developed to approval. Status: research chemical. Not approved; WADA-banned (S2).
Identity & type
- Molecular type
- peptide
- Origin
- First-generation GHRP — reliable GH spike but pronounced ghrelin-like hunger, so it is used by those struggling to gain mass.
Mechanism of action
GHS-R1a agonist with strong orexigenic (appetite) effect; moderately raises prolactin/cortisol.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for GHRP-6. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
100–300 mcg SC 1–3× daily before meals. Known for intense hunger in the first 20–30 minutes — the community uses it in bulking phases when eating enough is hard. GH effects: sleep, recovery, mild recomp.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Known for intense hunger in the first 20–30 minutes — the community uses it in bulking phases when eating enough is hard. GH effects: sleep, recovery, mild recomp.
Protocol — official vs community
Official / label
No approved product. The 'hunger GHRP' — strongest appetite stimulation in class.
Duration: Study use only.
Its ghrelin-mimetic hunger effect is the most reliable thing about it.
Community (anecdotal)
100–300 mcg SC 2–3× daily, deliberately around meals by users chasing mass.
- Cycle:
- 8–12 weeks.
- Break:
- 4 weeks off.
Chosen over ipamorelin specifically when appetite increase is the goal.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. Clinically investigated in the 1990s; never developed to approval.
Preclinical evidence
Clinically investigated in the 1990s; never developed to approval. Preclinical data also show cardioprotection.
Known risks
- Marked hunger, water retention, elevated prolactin/cortisol at higher doses.characterized
- Unregulated injectable supply — sterility, purity and accurate dose not assuredtheoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.